Amgen Inc. (AMGN) vs Bristol-Myers Squibb Company (BMY)
BMY leads on 10 of 17 compared metrics.
A side-by-side comparison of Amgen Inc. and Bristol-Myers Squibb Company across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 25, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
AMGN
Amgen Inc.
$376.04HealthcareAt close: Jul 24, 2026, 4:00 PM ET
BMY
Bristol-Myers Squibb Company
$62.09HealthcareAt close: Jul 24, 2026, 4:00 PM ET
Total return — AMGN vs BMY
growth of $100 · dividends reinvested · last 30yAMGN +4125.5%BMY +762.7%AMGN compounded faster
AMGN BMY
AMGN vs BMY: by the numbers
- •AMGN is the larger company ($202.95B vs $126.79B market cap).
- •BMY trades at the lower earnings multiple (17.44 vs 26.17 P/E).
- •AMGN converts more revenue to profit (20.95% vs 15.01% net margin).
- •AMGN grew revenue faster over the past five years (8.15% vs 2.52% CAGR).
- •BMY pays the higher dividend yield (4.03% vs 2.61%).
Which is better, AMGN or BMY?
Metric tally: AMGN 7 · BMY 10It depends on what you're optimizing for:
ValueBMY(lower P/E)
GrowthAMGN(faster 5Y revenue CAGR)
IncomeBMY(higher dividend yield)
QualityBMY(higher ROIC)
Metrics side by side
Valuation
| Metric | AMGN | BMY |
|---|---|---|
| P/E ratio | 26.17 | 17.44● |
| Forward P/E | 16.84 | 9.79● |
| P/S ratio | 5.49 | 2.62● |
| P/B ratio | 22.26 | 6.32● |
| PEG ratio | 0.26● | 1.86 |
| EV / EBITDA | 14.98 | 10.28● |
| FCF yield | 4.20% | 9.38%● |
Profitability
| Metric | AMGN | BMY |
|---|---|---|
| Gross margin | 71.46%● | 68.75% |
| Operating margin | 31.63%● | 25.67% |
| Net margin | 20.95%● | 15.01% |
| ROE | 84.87%● | 36.25% |
| ROIC | 13.16% | 13.90%● |
Dividends
| Metric | AMGN | BMY |
|---|---|---|
| Dividend yield | 2.61% | 4.03%● |
| Payout ratio | 68.39% | 72.25% |
Growth (annualized)
| Metric | AMGN | BMY |
|---|---|---|
| Revenue CAGR (5Y) | 8.15%● | 2.52% |
| EPS CAGR (5Y) | 2.94% | 9.38%● |
| FCF CAGR (5Y) | -2.66% | -2.50%● |
| Total return CAGR (5Y) | 12.18%● | 2.20% |
Frequently asked
- Which is better, AMGN or BMY?
- It depends on your goal. value: BMY (lower P/E); growth: AMGN (faster 5Y revenue CAGR); income: BMY (higher dividend yield); quality: BMY (higher ROIC). Across all compared metrics, BMY leads 10 to 7.
- Is AMGN or BMY cheaper?
- On trailing earnings, BMY is cheaper: AMGN trades at a 26.17 P/E and BMY at 17.44.
- Which has grown faster, AMGN or BMY?
- Over the past five years, AMGN grew revenue faster — AMGN at a 8.15% CAGR versus BMY at 2.52%.
- Does AMGN or BMY pay a bigger dividend?
- AMGN yields 2.61% and BMY yields 4.03% based on trailing dividends and the latest price.
- Is AMGN or BMY more profitable?
- AMGN runs the higher net margin — AMGN at 20.95% versus BMY at 15.01%.
- Which has been the better investment, AMGN or BMY?
- Over the past 10-year, AMGN delivered the higher annualized total return — AMGN at 11.82% versus BMY at 1.56%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Amgen P/E ratioBristol-Myers Squibb P/E ratioAmgen dividend yieldBristol-Myers Squibb dividend yieldAmgen ROEBristol-Myers Squibb ROEAmgen operating marginBristol-Myers Squibb operating marginAmgen revenue growthBristol-Myers Squibb revenue growthAmgen free cash flowBristol-Myers Squibb free cash flow
Amgen & Bristol-Myers Squibb appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 25, 2026.